Complement and immunity to viruses

Immunological Reviews

Volumn 159, Issue , 1997, Pages 69-77

  Lachmann, Peter J ^a   Davies, Alexandra ^a  

^a Centre for Veterinary Science   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; COMPLEMENT RECEPTOR;

BURKITT LYMPHOMA; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; EPSTEIN BARR VIRUS; HERPES VIRUS; HERPES VIRUS SAIMIRI; HOST RESISTANCE; HUMAN; HUMORAL IMMUNITY; MEASLES VIRUS; MICROGLIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SUBACUTE SCLEROSING PANENCEPHALITIS; VACCINIA VIRUS; VIRUS IMMUNITY; VIRUS INFECTION; VIRUS PARTICLE;

EID: 0030725195     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1997.tb01007.x     Document Type: Review

References (58)

1. Schultz DR. The complement system. Monogr Allergy 1971;6:74-75.
2. Berry DM, Almeida JD. The morphological and biological effects of various antisera on avian infectious bronchitis virus. J Gen Virol 1968;3:97-102.
3. Ehrnst A. Separate pathways of C activation by measles virus cytotoxic antibodies: subclass analysis and capacity of F(ab) molecules to activate C via the alternative pathway. J Immunol 1978;121:1206-1212.
4. Lachmann PJ, Hughes-Jones NC. Initiation of complement activation. Springer Semin Immunopathol 1984;7: 143-162.
5. Esser AF, Bartholomew RM, Jensen FC, Muller-Eberhard HJ. Disassembly of viral membranes by complement independent of channel formation. Proc Natl Acad Sci USA 1979;76:5843-5847.
6. Cooper NR, Jensen FC, Welsh RMJ, Oldstone MB. Lysis of RNA tumor viruses by human serum: direct antibody-independent triggering of the classical complement pathway. J Exp Med 1976;144:970-984.
7. Takeuchi Y, Cosset FL, Lachmann PJ, Okada H, Weiss RA, Collins MK. Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. J Virol 1994;68:8001-8007.
8. Takeuchi Y, et al. Sensitisation of cells and retroviruses to human serum by (alpha 1-3) galactosyltransferase. Nature 1996;379:85-88.
9. Bergmeier LA, Walker J, Tao L, Cranage M, Lehner T. Antibodies to human and nonhuman primate cellular and culture medium components in macaques vaccinated with the simian immunodeficiency virus. Immunology 1994;83:213-220.
10. Stott EJ, et al. Preliminary report: protection of cynomolgus macaques against simian immunodeficiency virus by fixed infected-cell vaccine. Lancet 1990;336:1545-1546.
11. Putkonen P, et al. Whole inactivated SIV vaccine grown on human cells fails to protect against homologous SIV grown on simian cells. J Med Primatol 1993;22:100-103.
12. Chan WL, et al. Immunisation with class I human histocompatibility leukocyte antigen can protect macaques against challenge infection with SIVmac-32H. AIDS 1995;9:223-228.
13. Nemerow GR, Jensen FC, Cooper NR. Neutralisation of Epstein-Barr virus by nonimmune human serum. Role of cross-reacting antibody to herpes simplex virus and complement. J Clin Invest 1982;70:1081-1091.
14. Apostolov K, Sawa MI. Enhancement of haemolysis by Newcastle disease virus (NDV) after pre-treatment with heterophile antibody and complement. J Gen Virol 1976;33:459-469.
15. Sissons JG, Oldstone MB, Schreiber RD. Antibody-independent inactivation of the alternative complement pathway by measles virus-infected cells. Proc Natl Acad Sci USA 1980;77:559-562.
16. Schreiber RD, Pangburn MK, Medicus RG, Muller-Eberhard HJ. Raji cell injury and subsequent lysis by the purified cytolytic alternative pathway of human complement. Clin Immunol Immunopathol 1980;15: 384-396.
17. Nelson B, Ruddy S. Enhancing role of IgG in lysis of rabbit erythrocytes by the alternative pathway of human complement. J Immunol 1979;122:1994-1999.
18. Fries LF, Gaither TA, Hammer CH, Frank MM. C3b covalently bound to IgG demonstrates a reduced rate of inactivation by factors H and I. J Exp Med 1984;160:1640-1655.
19. Reiter Y, Fishelson Z. Targetting of complement to tumor cells by heteroconjugates composed of antibodies and of the complement component C3b. J Immunol 1989;142:2771-2777.
20. Morgan BP, Dankert JR, Esser AF. Recovery of human neutrophils from complement attack: removal of the membrane attack complex by endocytosis and exocytosis. J Immunol 1987;138:246-253.
21. Schlager SI, Boyle MD, Ohanian SH, Borsos T. Effect of inhibiting DNA, RNA, and protein synthesis of tumor cells on their susceptibility to killing by antibody and complement. Cancer Res 1977;37:1432-1437.
22. Jahr H, Kruschel B, Walter BM, Kohnert KD. Complement-mediated cytotoxic effects of islet cell surface antibodies: factors influencing the sensitivity of the target cells. Biomed Biochim Acta 1984;43:641-646.
23. Lachmann PJ, Valdimarsson H, Agnarsdottir G. The aetiology of subacute sclerosing panencephalitis. In: Miescher PA, ed. Immunopathology VIIth Int Symp; 1976 Jun; Bad Schachen, Germany. Basel: Schwabe & Co. 1977. p.148-160.
24. Joseph BS, Oldstone MB. Immunologic injury in measles virus infection. II. Suppression of immune injury through antigenic modulation. J Exp Med 1975;141:864-876.
25. Gorman NT, Lachmann PJ. In vitro modulation of viral cell surface glycoproteins by anti-viral antibody in the presence of complement. Clin Exp Immunol 1982;50:507-514.
26. Allen IV, McQuaid S, McMahon J, Kirk J, McConnell R. The significance of measles virus antigen and genome distribution in the CNS in SSPE for mechanisms of viral spread and demyelination. J Neuropathol Exp Neurol 1996;55: 471-480.
27. McConnell I, Klein G, Lint TF, Lachmann PJ. Activation of the alternative complement pathway by human B cell lymphoma lines is associated with Epstein Barr virus transformation of the cells. Eur J Immunol 1978;8:453-458.
28. Halstead SB. Antibody, macrophages, dengue virus infection, shock, and haemorrhage: a pathogenetic cascade. Rev Infect Dis 1989;11:S830-839.
29. Reisinger EC, et al. Complement-mediated enhancement of HIV-1 infection of the monoblastoid cell-line U937. AIDS 1990;4:961-965.
30. Trischmann H, Davis D, Lachmann PJ. T lymphocytotropic strains of HIV type I when complexed with enhancing antibodies can infect macrophages via Fc gamma RIII, independently of CD4. AIDS Res Hum Retroviruses 1995;11: 343-352.
31. Thieblemont N, Delibrias C, Fischer E, Weiss L, Kazatchkine MD, Haeffnercavaillon N. Complement enhancement of HIV-infection is mediated by complement receptors. Immunopharmacology 1993;25:87-93.
32. Frade R, Barel M, Ehlin-Henriksson B, Klein G. gp140, the C3d receptor of human B lymphocytes, is also the Epstein-Barr virus receptor. Proc Natl Acad Sci USA 1985;82:1490-1493.
33. Dörig RE, Marcil A, Chopra A, Richardson CD. The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell 1993;75:295-305.
34. Naniche D, et al. Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J Virol 1993;67:6025-6032.
35. Manchester M, et al. Measles virus and C3 binding sites are distinct on membrane cofactor protein (CD46). Proc Natl Acad Sci USA 1995;92:2303-2307.
36. McNearney TA, Odell C, Holers VM, Spear PG, Atkinson JP. Herpes-simplex virus glycoproteins gc-1 and gc-2 bind to the 3rd component of complement and provide protection against complement mediated neutralization of viral infectivity. J Exp Med 1987;166:1525-1535.
37. Seidel-Dugan C, Ponce de Leon M, Friedman HM, Esenberg RJ, Cohen GH. Identification of C3-binding regions on herpes simplex virus type 2 Glycoprotein C. J Virol 1990;64:1897-1906.
38. Hung SL, Srinivasan S, Friedman HM, Eisenberg RJ, Cohen GH. Structural basis of C3b binding by glycoprotein-c of herpes-simplex virus. J Virol 1992;66:4013-4027.
39. Huemer HP, Wang Y, Garred P, Koistinen V, Oppermann S. Herpes-simplex virus glycoprotein-C: molecular mimicry of complement regulatory proteins by a viral protein. Immunology 1993;79:639-647.
40. Kostavasili I, Sahu A, Friedman HM, Eisenberg RJ, Cohen GH, Lambris JD. Mechanism of complement inactivation by Glycoprotein C of herpes simplex virus. J Immunol 1997;158:1763-1771.
41. Hung SL, et al. The interaction of glycoprotein-c of herpes simplex virus types 1 and 2 with the alternative complement pathway. Virology 1994;203:299-312.
42. Fries LF, Freidman HM, Cohen GH, Eisenberg RJ, Hammer CH, Frank MM. Glycoprotein C of Herpes simplex virus is an inhibitor of the complement cascade. J Immunol 1986;137:1636-1641.
43. Friedman HM, et al. Immune evasion properties of herpes simplex virus type 1 Glycoprotein gC. J Virol 1996;70:4253-4260.
44. Harris SL, Frank I, Yee A, Cohen GH, Eisenberg RJ, Friedman HM. Glycoprotein C of herpes simplex virus type 1 prevents complement-mediated cell lysis and virus neutralisation. J Infect Dis 1990;162:331-337.
45. Hidaka Y, Sakuma S, Kumano Y, Minagawa H, Mori R. Characterisation of glycoprotein C-negative mutants of herpes simplex virus type 1 isolated from a patient with keratitis. Arch Virol 1990;113:195-207.
46. Hidaka Y, Sakai Y, Toh Y, Mori R. Glycoprotein-c of herpes-simplex virus type-1 is essential for the virus to evade antibody-independent complement-mediated virus inactivation and lysis of virus-infected cells. J Gen Virol 1991;72:915-921.
47. Albrecht JC, et al. Primary structure of the herpesvirus saimiri genome. J Virol 1992;66:5047-5058.
48. Albrecht JC, Fleckenstein B. New member of the multigene family of complement control proteins in herpesvirus saimiri. J Virol 1992;66:3937-3940.
49. Randall RE, Newman C, Honess RW. Isolation and characterisation of monoclonal antibodies to structural and nonstructural herpesvirus saimiri proteins. J Virol 1984;52:872-883.
50. Fodor WL, et al. The complement control protein homolog of Herpesvirus saimiri regulates serum complement by inhibiting C3 convertase activity. J Virol 1995;69:3889-3892.
51. Russo JJ, et al. Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8). Proc Natl Acad Sci USA 1996;93: 14862-14867.
52. Albrecht JC, Nicholas J, Cameron KR, Newman C, Fleckenstein B, Honess RW. Herpesvirus saimiri has a gene specifying a homolog of the cellular membrane glycoprotein CD59. Virology 1992;190:527-530.
53. Rother RP, et al. Inhibition of complement-mediated cytolysis by the terminal complement inhibitor of herpesvirus saimiri. J Virol 1994;68:730-737.
54. Bramley JC, Davies A, Lachmann PJ. Herpesvirus saimiri CD59 - baculovirus expression and characterisation of complement inhibitory activity. Biochem Soc Trans 1997;25:354S.
55. Kotwal GJ, Isaacs SN, Mckenzie R, Frank MM, Moss B. Inhibition of the complement cascade by the major secretory protein of vaccinia virus. Science 1990;250:827-830.
56. Isaacs SN, Kotwal GJ, Moss B. Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence. Proc Natl Acad Sci USA 1992;89:628-632.
57. McKenzie R, Kotwal GJ, Moss B, Hammer CH, Frank MM. Regulation of complement activity by Vaccinia virus complement-control protein. J Infect Dis 1992;166:1245-1250.
58. Engelstad M, Howard ST, Smith GL. A constitutively expressed vaccinia gene encodes a 42-kda glycoprotein related to complement control factors that forms part of the extracellular virus envelope. Virology 1992;188:801-810.